Allosteric mTOR inhibitors such as Rapamycin derivatives or rapalogs are approved for clinical use in limited cancer types, while a variety of less selective ATP-competitive mTOR, PI3K or AKT or duel mTOR/PI3K multikinase inhibitors are still in clinical development [1, 2]. The gene discussed is AKT1; the disease is cancer.